SCHEMBL13617063

SCHEMBL13617063

CN1CCC(n2ncc3c(Oc4ccccc4)ncnc32)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.53
BTK Q06187 5/20 0.51
NUDT14 O95848 1/20 0.51
NUDT5 Q9UKK9 1/20 0.51
SLC2A1 P11166 1/20 0.44
SLC2A2 P11168 1/20 0.44
SLC2A3 P11169 1/20 0.44
LCK P06239 3/20 0.43
SRC P12931 2/20 0.43
KDR P35968 2/20 0.43
TEK Q02763 2/20 0.43
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FLT3 P36888 3/20 0.42
ABL1 P00519 2/20 0.41
LYN P07948 2/20 0.41
AKT2 P31751 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13617064 0.89 CYP3A4 (0.48) CYP3A4BTKNUDT14NUDT5SLC2A1
SCHEMBL1128417 0.85 CYP3A4 (0.60) CYP3A4BTKSLC2A1SLC2A2SLC2A3
SCHEMBL1128336 0.82 CYP3A4 (0.79) CYP3A4SRCABL1EGFRAURKB
SCHEMBL1128724 0.82 CYP3A4 (0.61) CYP3A4
SCHEMBL2019853 0.80 CYP3A4 (0.61) CYP3A4BTKRETEGFR
SCHEMBL2016500 0.80 CYP3A4 (0.79) CYP3A4BTKSRCEGFRAURKB
SCHEMBL19140501 0.80 SIGMAR1 (0.51) BTKNUDT14NUDT5SLC2A1SLC2A2
SCHEMBL4352334 0.78 CYP3A4 (0.62) CYP3A4BTKSLC2A1SLC2A2SLC2A3
SCHEMBL4351830 0.77 CYP3A4 (0.54) CYP3A4BTKRAB9AFLT3ABL1
SCHEMBL4360972 0.77 CYP3A4 (0.60) CYP3A4BTKNPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 CYP3A4 1503/4885BTK 4379/4885NUDT14 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.